Landau, H <br/><br/>
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.  [electronic resource] 

 -  Leukemia  Apr 2013 
 - 823-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2012.274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Amyloidosis--drug therapy<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Dexamethasone--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Pyrazines--administration & dosage<br/>Stem Cell Transplantation